ALHCAlignment Healthcare, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.
Priced for ~9% a year FCF growth. The price demands less than its three-year revenue growth of 41% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ALHC's price assumes
Alignment Healthcare, Inc. trades at 39.7× earnings against 25.0× for the median Healthcare Plans name, more expensive than its own group.
Trailing P/E · Healthcare Plans median 25.0 · 1.59× the median: the market pays up for this one
- Price / sales
- 1.03
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 3.8%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- +9.3%
Growth the price implies · The price pays for +9.3% free cash flow growth a year for a decade; the business has delivered +57% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 17.7
- EV / EBIToperating margin 1.2%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.94
- Healthcare median P/E509 names
- 26.2
- Healthcare Plans median P/E11 names
- 25.0
- Free cash flow, trailing twelve months
- $178M
- Market capitalisation
- $4.69B
- 3-year revenue growth
- +41%
- 3-year free cash flow growth
- +57%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Healthcare
Ranks #214 of 446 by RyuScore